Investment Thesis
Lantern Pharma is a pre-revenue biotech company with severe financial distress, burning $15.7M annually while holding only $4.4M in cash, implying a ~3.5-month runway. Despite marginal year-over-year improvement in net losses, the company lacks revenue generation, has a microscopic balance sheet ($11M assets), and faces imminent capital needs that will likely trigger significant shareholder dilution.
Strengths
- Net loss improving 17.6% year-over-year showing operational cost discipline
- Zero debt obligation eliminates financial leverage risk and interest burden
- Current ratio of 2.40x and quick ratio of 2.40x indicate adequate short-term liquidity on balance sheet
Risks
- Pre-revenue company with zero income-generating operations and undefined path to monetization
- Operating cash burn of $15.7M annually against $4.4M cash reserves indicates critical runway of ~3.5 months without capital raise
- Extremely thin equity base of $6.5M and total assets of $11M provide minimal financial cushion for R&D or operational setbacks
- High probability of dilutive capital raise or debt financing in near term to avoid insolvency
- Pharmaceutical development carries inherent pipeline risk with potential for clinical failures
Key Metrics to Watch
- Monthly cash burn rate and projected runway to profitability or funding need
- Clinical trial progress and any regulatory milestone announcements
- Capital raise announcements and dilution impact on existing shareholders
- Operating expense trends and burn rate trajectory
Financial Metrics
Revenue
N/A
Net Income
-17.1M
EPS (Diluted)
$-1.57
Free Cash Flow
-15.7M
Total Assets
11.0M
Cash
4.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-262.0%
ROA
-155.1%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.40x
Quick Ratio
2.40x
Debt/Equity
0.00x
Debt/Assets
40.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-12T21:09:23.033230 |
Data as of: 2025-12-31 |
Powered by Claude AI